Invent Penn State is pleased to usher in an exciting new event—the first ever Invent Penn State Venture & IP Conference. The goal of the event is to bring together promising technology companies from across the country with investors seeking ground-floor investment opportunities. This is an exclusive forum for industry, investors, and start-ups to see disruptive innovations from Penn State’s faculty and student entrepreneurs as well as alumni start-ups. This inaugural event will showcase groundbreaking innovations, intellectual property, start-ups, and technology companies from sectors including life sciences, agriculture, energy, materials, advanced manufacturing, educational technology, and communications.
Learn more about what this conference means for the Centre Region.
Tucked away in a quiet corner of the Technology Center at Innovation Park, you’ll find the offices of Don McCandless and Jim Pietropaolo. Experts in technology start-ups, they serve as Directors of Business Development for Ben Franklin Technology Partners, an economic development program with 30+ years of experience helping technology companies grow.
McCandless and Pietropaolo are resources for start-ups that participate in the TechCelerator program (mentoring sessions to help launch technology-based start-ups) and for individuals who have intellectual property and are looking for business advice. They urge all researchers with an idea and intellectual property to utilize their services.
Keystone Nano Tests Promising New Cancer Treatments
Keystone Nano, a State College-based biopharmaceutical company, is developing new treatments in the fight against cancer and its new, potentially ground-breaking therapies could be available sooner rather than later.
The company is currently developing three different approaches to cancer therapy with products that address liver cancer, leukemia, and breast cancer.
Voxello: Giving a Voice to Hospitalized Patients
In the U.S. alone, there are 3.9 million hospitalized patients who can’t communicate their needs to nurses. Without proper means of communication, these patients are three times more likely to experience preventable complications, such as adverse reactions to medicine.
Voxello, led by CEO Rives Bird, has created an innovative solution. Bird brings more than 20 years of experience as an executive in multiple medical device companies, and has launched multiple successful entrepreneurial ventures in Iowa.
INDIGO Biosciences Reduces the Time and Cost of Drug Discovery
INDIGO Biosciences, Inc., founded in 2005 in State College by Dr. Jack Vanden Heuvel and Dr. Blake Peterson, is a biosciences company focused on nuclear receptors, which make up a major class of therapeutic drug targets. The company has the largest global portfolio of nuclear receptor (NR) assay kits and related screening services.
INDIGO Biosciences’ original focus was to provide custom services for the screening of small molecule compounds against functional human and non-human nuclear receptors.
Over the years, the company has demonstrated success in providing quality screening services to clients within the pharmaceutical, biotechnology, food, agriculture, and nutriceutical industries, government research agencies, as well as to academic researchers.